Abstract
Background: Economic evaluation guidelines (EEGs) serve as a valuable tool to assist appraisers in making consistent and transparent recommendations, standardize EE studies, enhance their quality, and minimize methodological uncertainties. As other LMICs, Lebanon aims for UHC where EEG is a necessity. This paper aims to report on the Lebanese health EEG (LEEG) and its reference case, including the intermediate results leading to the final decisions. Research design and methods: The LEEG followed a structured, systematic, and transparent process: (1) identifying the rationale and the guideline scope; (2) establishing the Guideline Development Group; (3) searching the evidence; (4) planning the development process; (5) selecting the panel for the deliberative process; (6) surveying Lebanese stakeholders; (7) deliberating on the results; (8) drafting the guideline; and (9) consulting with international experts. Results: The LEEG includes three general characteristics, 19 key features, a reference case, and an action plan. Conclusions: The LEEG is the first national EEG for health interventions. It will help decision-makers, researchers, and healthcare providers improve the quality and assessment of EE in Lebanon to identify the most cost-effective health interventions. Implementing LEEG is crucial to promoting an equitable, efficient, and high-quality health system with a more consistent decision-making process.
Original language | English |
---|---|
Pages (from-to) | 551-565 |
Number of pages | 15 |
Journal | Expert Review of Pharmacoeconomics & Outcomes Research |
Volume | 25 |
Issue number | 4 |
Early online date | 8 Jan 2025 |
DOIs | |
Publication status | Published - 2025 |
Keywords
- Lebanon
- economic evaluation
- economics pharmaceutical
- guideline
- low- and middle-income countries
- reference case